Targets Identification for Bladder Cancer
Drug targets and modes of action remain two of the biggest challenges in modern drug discovery and development. At Alfa Cytology, we have established a comprehensive platform to support the target identification (ID) of bladder cancer targets in different therapeutic areas.
Introduction to Targets Identification
Drug target refers to the direct binding site of a drug to a biomolecule in the organism, which mainly includes receptors, enzymes, ion channels, transporters, nucleic acids and other biomolecules. Target identification plays a crucial role in the development of effective therapies for bladder cancer. It involves the identification and validation of specific molecules or biological pathways that are dysregulated in cancer cells and contribute to tumor growth and progression.
By targeting these molecules or pathways, researchers can potentially develop novel therapeutic interventions that selectively inhibit cancer cell growth while minimizing harm to normal cells.
Fig 1. Approaches for target identification. (Rasul A., et al. 2021)
- Affinity-based Approaches: Rely on direct interaction of proteins with small molecules.
- Phenotype-based Approaches: The methods and techniques that are meant to compare the biological profiles of small molecules with already known reference drugs.
- The Genetic-based Approaches: Identifying the genes that are responsible for drug resistance produced by small molecules, as well as small molecule-sensitive clones.
- Computational Approaches: Predicting the drug targets on the basis of chemical complementarity between the proteins and molecules of interest.
Our Services
Relying on high-resolution mass spectrometry platform, combined with affinity chromatography and active-site directed probe technology, Alfa Cytology has developed and validated a variety of small molecule target identification platforms. Our target-based small molecule drug target identification solutions include:
| Our Services |
Principles |
Workflows |
Advantages |
Affinity-based Approaches
Drug affinity responsive target stability |
Dependent on conferring protection from protein hydrolysis on target proteins through interaction with small molecules. |
 |
- Non-labelled
- Directness
- Fidelity
- Wide applicability
- Timeliness and economy
|
Phenotype-Based Methods
Activity-based protein profiling (ABPP) |
Combining activity-based probes and proteomics technologies for identifying protein targets of small molecules or even active sites of target proteins. |
 |
- Specificity
- Functional analysis
- Real-time monitoring
- Non-invasive labelling
- Sample applicability
|
The genetic-based Approaches
CRISPR-Cas9 / RNAi |
The combination of high-throughput gene knockout technology and mass spectrometry not only enables the rapid identification of new drug targets, but also provides an in-depth understanding of the drug's mechanism of action. |
 |
- Specificity
- High Efficiency
- Versatility and Flexibility
- Functional Validation
- Cost-Effectiveness
|
Computational approaches
Molecular Docking |
Computational modeling and prediction of the binding interactions between a small molecule (ligand) and a target protein. |
 |
- Time Efficiency
- Cost Efficiency
- Large-Scale Screening
- Rational Design
|
Contact Us
At Alfa Cytology, we are dedicated to supporting your bladder cancer research and development needs. Our team of experienced scientists and researchers is ready to assist you in every step of your project, from protocol design to project completion. We offer a wide range of products, services, and solutions that can help accelerate your research and facilitate the identification of targets for bladder cancer. If you have any needs, please contact us today.
Reference
- Rasul A., Riaz A., et al. Target Identification Approaches in Drug Discovery[M]//Drug Target Selection and Validation. Cham: Springer International Publishing. 2022: 41-59.
For research use only. Not intended for any clinical use.
Related Services
